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It is difficult to understand why some premenopausal women with breast cancer
succumb quickly to metastatic cancer after localtreatment, whereas others with ap-
parently comparable stages of disease are cured by resection or other local treat-
ment . Breast cancers arising in humanbeings and mice are oftenhighly responsive
to changes in sex hormone concentrations or drugs that change the ability ofthese
hormones to bind to their receptors or transduce the resultant message to the ge-
nome of the breast cancer cell . These responses frequently include total disappear-
ance of all evidence of breast cancer formany years . The menstrual cycle in women,
or estrous cycle in the female mouse, is responsible for precisely timed high ampli-
tude and well-coordinated fluxes ofa series of powerful hormones that have many
important and predictable physiologic, biochemical, and immunologicconsequences
(1) . With this in mind, we have studied the relationship between the estrous cycle
in the mouseandthemetastatic potential ofatransplantable estrogen receptor-bearing
mammary adenocarcinoma .
The C3HeB/FeJ mouse is an inbred animal that allows growth of a transplanted
mammary tumor that originated spontaneously in a C3H inbred mouse. The
C3HeB/FeJ mouse does not harbor the virus that causes mammary adenocarcinoma
in the C3H mouse and therefore will not transmit the virus to its young by suck-
ling. Themammaryadenocarcinoma used in this study has repeatedly been shown
to be relatively rich in estrogen receptors (2). As is the case in the human disease,
when the C3HeB/FeJ mouse is implanted with this mammary adenocarcinoma and
the tumor is surgically removed afterseveralweeks of growth, not every mouse dies
of subsequent metastases (3).
In an attempt to better understand the basis for this biological heterogeneity, we
hypothesized that the stage of the estrous cycle ofan individual animal at the time
oftumor implant and/or primarytumor resection mightinfluence metastatic poten-
tial. In addition, this study defined the estrous periodicity of cell types in vaginal
smears of the C3HeB/FeJ mouse, determined if this periodicity changed upon in-
troduction ofan estrogen receptor-bearing mammary adenocarcinoma, and deter-
This work wassupportedby the Potts Foundation grant 842-24-000 and by National Cancer Institute
grantR01CA-31635 .H.V . Ratajczak's present address is IITResearch Institute, Life Sciences Depart-
ment, Chicago, IL 60616 . Address correspondence to Dr. WilliamJ .M . Hrushesky, Dept . ofMedicine,
Box 414, UMHC, University of Minnesota, Minneapolis, MN 55455 .
Apreliminary report onportions ofthis work was presented in part at the Second Montreux Confer-
ence on Chronopharmacology, March 10-14, 1986, Montreux, Switzerland .
J . EXP. MED . © The Rockefeller University Press - 0022-1007/88/07/0073/11 $2.00
￿
73
Volume 168 July 1988 73-8374
￿
ESTROUS ROLE IN SURGICAL CURE OF MOUSE BREAST CANCER
mined whether the estrous periodicity changed again upon removal of the tumor-
bearing leg or amputation of a normal leg in control mice.
Our results demonstrate that the presence of a transplanted syngeneic estrogen
receptor-bearing tumorpredictably affects the estrous cycle and, more importantly,
that the timing within the estrous cycle of surgical removal of this tumor, regardless
ofits size, profoundlyinfluencesthe expression ofsubsequenttumorcell metastasis.
Materials and Methods
ExperinuntalApproach.
￿
176 female C3HeB/FeJ mice (TheJackson Laboratory, Bar Harbor,
ME) at least 10 wk old were housed five per cage with lights on for 12 h of each 24-h day
(lights on 06°°-18°°, lights off 18°°-06°°, local time) with food (laboratory chow) and water
available ad libitum. At daily intervals, a total of9,761 vaginal smears were obtained between
2 and 6 h after light onset (49-66 smears/mouse) (Table I). A drop from a Pasteur pipette
of sterile PBS (pH 7.2) was added to the vagina and the fluidwas aspirated immediately and
transferred to a glass slide. Slides were stained with hematoxylin and eosin.
The tumor used in these studies was a spontaneous mammary adenocarcinoma that arose
in a female C3H mouse and that was repeatedly carried by subcutaneous transplantation
in female C3HeB/FeJ mice. Malignant cells were isolated from a tumor -10 mm in diameter,
minced with scissors, and suspended in Medium 199 (Gibco Laboratories, Grand Island,
NY) supplemented with penicillin (P, 50 U/ml) and streptomycin (S, 50 wg/ml). Cell via-
bility was assessed by trypan blue dye exclusion. Transplantation was accomplished by subcu-
taneous injection of 2 x 105 viable cells suspended in 0.1 ml medium into the left hind leg
at the base ofthe tibia. 14-17 d afterinoculation, the primary tumor was first measured (length
x width in millimeters) and then removed by amputation of the leg at the proximal end
ofthe femur while the animal was under light Metofane® anesthesia. 30 normal animals had
their left hind legs similarly amputated and they served as a control for assessing the effect
of operation alone.
Mice were singly housed after amputation and daily vaginal smears were obtained at the
same time ofday for the ensuing 28 d. At this point all 132 surviving original tumor bearers
were killed by cervical dislocation and lung metastases were noted and measured with a cal-
iper (length x width in millimeters).
Bio-assay and Vaginal Cell Quantification.
￿
Each mouse without visible metastases was fur-
ther studied using a bio-assay for metastases. The lungs ofeach apparently tumor-free an-
imal were minced in RPMI-1640 (Gibco Laboratories) supplemented with P and S and half
of the suspension was injected subcutaneously into each of the shaved flanks of a normal
syngeneic mouse (one donor per recipient). These recipient mice were subsequently observed
for tumor growth for 4 mo. The frequencies of grossly visible metastases and bio-assay posi-
tivity for metastatic disease were then compared with regard to the size oftumor at resection
and also with regard to the cellular pattern in the vaginal smear (estrous stage) at the time
of initial tumor implant and the time of surgical removal of the primary transplanted tumor
by amputation.
It is well established that cell types of vaginal smears indicate stage of the estrous cycle.
In this investigation, no studies were done to correlate cell types in vaginal smears with hor-
monal status or reproductive changes physiologically. Therefore, in this investigation vaginal
cell types were scored on a plus basis: leukocytes (L) were either absent, 1 ' , 2' , or 3' . Like-
wise, cornified epithelial cells (C) were either absent or 1', 2', or 3' . Combined cellularity
of the vaginal smears with regard to these two cell types was then scored between 0 and 6.
Nucleated epithelial cells were relatively constant in number and were not included in this
analysis. An arbitrary division separating the cellularity equally was made at 0-3 and 4-6,
roughly approximating proestrus/estrus and metestrus/diestrus, respectively. The incidence
of surgical cure was then compared as a function ofwhether few or many leukocytes and/or
cornified epithelial cells were present in the vaginal smear on the day of tumor transplant
and tumor resection or amputation. Seven mice with recurring local tumor growth at the
site of resection and six mice that died early in the study from surgical complications had00
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to be excluded from analysis for metastatic potential . Onemouse died with metastases present
24 d after leg amputation and was included in final calculations .
Results
Expression ofMetastases vs. Time ofPrimary TumorRemoval.
￿
Whilethe eventual inci-
denceofpulmonary metastases was not influenced by vaginal smear content (estrus
stage) on the day of tumor implantation (x2 = 0.40, p = 0.53), the time of resec-
tion of the tumor-bearing limb markedly influenced the incidence of pulmonary
metastases 28 d later. 36 of 133 mice (27%) were apparently disease free by gross
inspection of the lungs 28 d after amputation of the primary tumor (Fig . 1, left) .
40% (24 of60)of themice with small amounts(0 to 3) ofL+C cells on day oftumor
resection were grossly disease free, while only 16.4% (12 of 73) with large amounts
(4-6) ofL+C cells on day of resection were disease free at this point of the study
(x2 = 9.26, p = 0.002). Bioassay using the lungs of animals that were grossly free
of metastases resulted in sometumor induction in recipient mice, reducing the final
bio-negative, disease-free totals to 16 of 60 (27%) forL+C = 0-3, and9 of 73 (12.3%)
for L+C = 4-6 (x2 = 4.44, p = 0.035) (Fig. 1, right; Table II) .
Expression ofMetastases vs. Primary Tumor Size.
￿
A statistically significant difference
in mean tumor sizes at resection among the five groups of tumor-bearing animals
was found by analysis of variance (ANOVA : F = 132.6, p< 0.0001) . In addition,
two distinct but separate normal distributionsoftumor sizeswere found at resection
FIGURE 1 .
￿
Cell types in vaginal smear at
time of surgical removal of transplanted
estrogen receptor-bearing tumor signifi-
cantly affect whetheror not metastases ul-
timately appear in female mice. Grouping
consisted ofmicewith low total cell counts
(0-3), indicating near or in estrus (highest
fertility) and mice with high total cell
counts (4-6), indicating a post-estrus stage
(lowest fertility). 132 mice were killed 28
d after amputation andmetastases in the
lungs were counted (one mouse with meta-
stases died 4 d before it would have been
killed, and was included fora total of 133
mice) . At this time,40% ofmice with low
cell counts were disease free as compared
with only 16.4% ofthe mice with high total
cell counts (x2 = 9.26, p = 0.002) . 5 mo
after leg amputation, 26.7% ofmice with
low cell counts were classified as bio
(disease free), as compared with only
12.3% of mice with high total cell counts
(x2 = 4.44, p = 0.035) .
* No evidence of disease.RATAJCZAK ET AL.
￿
77
TABLE II
Metastasis depends upon time of tumor removal
Metastatic incidence grouping mice by numbers ofleukocytes (L) and cornified (C) cells ob-
served in vaginal smear on day of primary tumor removal . Mice with grossly apparent
metastases on day 28 were coded as "yes (gross)." Lung tissue, disease free at this time, was
minced and implanted into naive mice (bioassay), who were observed for 4 mo . If, after
this span, tumors appeared, the animal from whom lungs were taken was coded as "bio'
and if no tumor appeared the donor animal was coded as "bio ."
* Not visible .
with mice in Study 2 displaying smaller tumors than thosein the other four groups .
Although mice in Study 2 (late November, 18 wk old at start of study) had mean
tumor sizes (in mm2) nearly a third of that of the other mice (45 t 2 [SE], n =
54), astatistically significant difference wasalso observed amongtheremaininggroups
ofmice (F = 7.6,p = 0.0002 from ANOVA) . The mean sizes oflarger tumors ranged
from 105 mm2 t 4 for group 4 (studied late in December) to 128 mm2 f 6 SE
for group 1A (studied in mid-November). Aswouldbe expected, therewasasignificant,
but relatively unimpressive, correlation oftumor size at resection and the number
ofpulmonarymetastases present 28 dlater (r = 0.33), as well as theabsolute volume
of those pulmonary metastases (r = 0.26) . However, this was brought about by the
two separatetumor size populations, since if small andlargetumor populations(Study
2 vs . other studies) were handled separately, there was no correlation of primary
tumor size and number or size of metastases. In fact, actual incidence (as opposed
to number or size) ofpulmonary metastases between Study2 (with smallertumors)
and the other studies (with larger ones) was not significantly different (%2 = 1.81,
p < 0.20) for 36 of 54 mice in Study 2 vs . 61 of 79 in the remaining studies .
To normalize tumor sizes among study groups for subsequent analyses, each in-
dividual tumor size was reexpressed as a percentage ofmean tumor size of all mice
in the respective study group . This resulted in a normal distribution oftumor sizes
for all 133 mice, with individual sizes ranging from 26 to 204% ofmean size (mean
= 100% ± 2 .4). After normalization of primary tumor sizes to percent of group
mean sizes, there was no correlation oftumor size with number nor size ofpulmo-
nary metastases forthe entire groupof 133 mice (r = -0.004 forboth correlations) .
A t test comparing primary tumor sizes of mice at resection that did not display
metastases (99.97% t 4.40) vs . those that did (100.01% t 2 .84) was not significant
at 28 d (t = 0.01, p = 0.993), norat 4mo (100.81% t 2.62 vs. 96.33 t 5.84, respec-
tively; t = 0.72, p = 0.473) . A comparison ofprimary tumor sizes vs . vaginal cel-
lularcounts at time of resectionwasnot significant when the 133 mice were divided
Sub-
grouping Metastases
Score
0-3
of L + C/number
(percent of total) :
4-6
of mice
X2 p value
1 Yes (gross and bio') 44(73.3%) 64(87.7%)
4.44 0.035
No (bio) 16(26.7%) 9(12.3%)
2 Yes (gross only) 36(60.6%) 61(83.6%)
9.26 0.002
No* (bio' and bio-) 24(410.0%) 12(16.4%)
3 Yes (gross only) 36(60.07 .) 61 (83 .6%)
No* (bio') 8(13.3%) 3 (4.1%) 9.50 0.009
No (bio) 16(26.7%) 9 (12.3%)78
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FIGURE 2 . Distribution of estrous cycle
lengths in C3HeB/Fej mice determined by
using thesum ofcornified cells plus leukocytes
(both noted on a scaleof0-3) observed in daily
vaginal smears . To estimate the average peri-
odicity ofcell type occurrence for each mouse,
each ofthe series wasdivided into three parts
representing the intact span (covering 22-24
d for 30 mice before tumor inoculation and
22-38 d for 30 control mice before legampu-
tation), the tumor-bearing span (14-17 d for
89 mice) and post amputation (28-42 days
after removal ofthe leg for all mice, including
30 micewithouttumor inoculation) (see Table
I). Each time series ofLorC combined scores
was analyzed by the least-squares fit ofcosine
curves with trial periods between 3 and 12 d
and with 6-h increments bet:,een triz 1 periods
(4) . The length of the best-fitting curve, indi-
cating the average time between maximalor
minimal occurrence ofL, C, or L+C, during
the spans of interest was then compared
statistically using Students t test in order to
compare the data from each mouse and the
behavior of the group mean period lengths .
into low counts (0-3) and high counts (4-6) (97.1% t 3 .5 for n = 60 vs . 102.3%
t 3.2 for n = 73 ; t = 1.08, p = 0.28) . This was also true for the 26 mice with
vaginal counts at time of tumor inoculation (t = 1.24, p = 0.226) .
At 28 d after resection, the mean tumor size for mice not displaying pulmonary
metastases was 101.9% ± 5.9 for 29 mice withC+L = 0 and 3, and 94.1% t 5 .4
for 12 mice with C+L = 4-6 . The mean tumor sizes for mice with metastases at
28 d were 94.0% ± 4.4 for 36 mice with C+L = 0-3 and 104.0% ± 3 .7 for 61
mice withC+L = 4-6 . A two-wayANOVAcomparingthe interaction of theresected
tumor size with vaginal cellular counts at resection and expression of pulmonary
metastases showed no effect ofprimary tumor size for 133 mice at 28 d (F = 2.50,
p = 0.117), nor at 4 mo (F = 0.49, p = 0.486) . These results were similar when
comparing resected tumor size and metastatic incidence with vaginal cell counts
available for 26 mice at inoculation .
It was thus clear that resected tumor size was not solely responsible for the devel-
opment of subsequent pulmonary metastases and that at least one other important
factor was influencing and overriding the anticipated correlation oftumor size itself
with metastatic potential . This factorwasthe timing ofresection within the mouse's
estrous cycle .
Estrous CycleLength.
￿
In defining the periodicity ofLandC cells in vaginal smears
of the C3HeB/Fej mouse, cosines with trial periods between 3 and 12 d were tested
with 6-h increments betweenperiods (4). The best-fitting estrous periodicity before
tumor transplant was defined as being, on average, 5.05 t 0.30d (Fig . 2 and Table
III) . Presence ofavery small and growing tumor increased the averageperiod length
to 6.61 t 0.31 d (t = 3.42, p = 0.001). Lengtheningof periodicity of cells in vaginal
smears by presence of a tumor is not a novel observation and was reported as early
as 1922 (5) . Tumor removal by amputation ofthe tumor-bearing leg resulted in theTABLE III
Average Period Length of Estrous Cycle,for Mice Before, During, and After Bearing an
Implanted Mammary Adenocarcinoma andfar Control Mice Before and After
Removal of a Non-Tumor-bearing Hind Leg
Group
Normal
Tumor
Normal
Tumor
Periodicity of cell types in vaginal smears determined by best-fitting cosine curves (with trial
windows from 3 to 12 d) .
recise return to a normal period length of 5.10 ± 0.16 d (t = 4.73,p< 0.001) .
five mice ($7o) thathad 12-d periods in the intact
group, and 15 mice (17%) with 12 d periods in the tumor-bearing group. Thereason
for these long cycles is not known with certainty but probably relates to individual
mice infrequently skipping estrus . Fig. 2 clearlydemonstrates the behavior ofestrus
hese outliers as well as the overall lengthening and shortening of estrous cycling
e remainder of the animals . Amputation of a tumor-bearing leg caused most
animals to revert to shorter cycles . The length of the period of 30 normal animals
(4.6 ± 1.4 d) wasunaffected by surgery (t = 0.55,p = -0.59) andwas not significantly
different from mice whose tumors had been resected (t = 1.57, p = 0.12).
analyses area refinement of results reported earlieron reversion of the estrous cycle
to normal duration after surgical removal of the tumor (6).
IfL alone orC alonewere used in the described periodicity analysis, very similar
results occurred (Table III) . L alone followed the same pattern as the combination
ofL+C with significant differencesbetween theestrous cyclelength oftumorbearers
and those before or after tumor . The estrous period defined byC alone showed no
ificantchange when animalswere giventumorbutdidshorten significantlywhen
tumor was removed .
RATAJCZAK ET AL .
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Discussion
Presently, premenopausal women with larger primary tumor (?1-inch diameter)
or axillarylymph node involvement withtumor (clinical stage II breast cancer) are
routinely subjected to high-dose intensity multi-agent chemotherapy given every 3
to 4 wk for 6-12 mo after total resection of the primary tumor . This approach has
Significance (p value from t test):
Spans compared t P t p t
None vs . surgery 2.08 0.042 2.31 0.024 0.55 0.586
None vs . tumor 3.85 <.001 0.46 0.460 3.42 0.001
Tumorvs . surgery 7.47 <.001 3.76 <.001 4.73 <.001
None vs . surgery 1.20 0.230 4.05 <.001 0.15 0.877
of estrous period (days t SE)
Treatment N Leukocytes (L)
observed for cell types :
Cornified cells (C) L + C
None 30 5.09 t 0.44 7.50 t 0.58 4.88 f 0.38
Surgery 28 4.15 t 0.07 5.60 t 0.58 4.59 t 0.35
None 60 4.83 f 0.25 7.67 t 0.40 5.05 t 0.30
Tumor 60 6.33 t 0.28 7.42 t 0.36 6.61 t 0.31
Surgery 167 4.57 f 0.10 5.86 t 0.21 5.10 f 0.1680
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been proven to prevent breast cancer relapseand improve long-term survival ofthese
high risk patients . A consensus meeting of breast cancer experts has agreed that
the benefit conferred by aggressive adjuvant chemotherapy in these women raises
their probability of long-term disease-free survival by between 9 and30% (7) . Our
data clearly show that, according to how the fertility cycle is partitioned and refer-
enced, tumor resection is curative at least twoor three times as frequently depending
uponwhen in themouse's cyclethe operation is performed. Surgical cure is reprodu-
ciblymost frequent when the operation is performedjust before and during thespan
commonly associated with ovulation . This phase is a time associated with high am-
plitude rhythmic surges of estrogen . Fatal metastatic disease occurs most reprodu-
cibly when the primary tumor is resected at the time in the cycle associated with
the lowest fertility, metestrus in mice, which is comparable to the timearound men-
struation in women, a time of rhythmic estrogen withdrawal .
Patients, who are identical with regard to the size of the primary cancer, stage
ofdisease at diagnosis, hormonal receptor status, andthenumber of axillary lymph
nodes involved by cancer, frequently have vastly differentoutcomes . These observa-
tions have led to studies concerned with the factors that influence the "metastatic
potential" oftumor cell clones . A great deal of this work has focused upon the cel-
lular, biochemical, and genetic basis by which tumor cells differ in their metastatic
potential (8-10) . Another large body of work highlights the host, its defenses, its
neurohumoral influence over the cancer cells, and how these factors might help to
determine theultimate clinical outcome . This report focuses on the biological con-
sequencesof rhythmic hormonal changes in thehost andhowthosehormonal changes
affect the interaction of tumor cells and host tissues.
It has alreadybeen shown, forexample, that thebalancebetween host andtumor
changes predictably as a function of time of day and from season to season, as well
as over the course of disease progression (11-19) . Our present data indicate that a
complex"crosstalk"between this transplanted malignancyand itsmurine host results
in a predictable effect of the tumorupon the mouse's estrous cycling and a predict-
ably differentmetastatic behavior depending upon when in the animal's estrous cycle
the primary tumor is resected. While the time of estrous cycle of tumor implant
played no role in eventual metastasis of the tumor, ultimate outcome is apparently
theresult of the interaction ofstress hormones and sexhormones at the time of surgery .
Surgically induced changes in the balance between the host and cancer are there-
fore associated with predictable stress/sex hormone interactions of probable impor-
tance to : the biology of host tissues destined to receive circulating metastatic cells
(in this case, the lung) ; the biology of the circulating tumor cells themselves (their
ability to implant, traverse boundaries, produceautocrineor paracrine growth factors,
induce new vessel formation and enter and remain in active cell division phase) ;
and/or upon theabilityofthehost immune system to effectively counter the metastatic
process (20) . The experiments summarized here cannot sort this out, but point the
way toward pertinent research in each of these separate areas . Because estrogenic
effects upon NK activity have been suggested (21), experiments investigating cel-
lularimmunity, as well as host andtumortissue at different estrous stages, arenecessary
to fully elucidate the complex interactions responsible for the estrous stage depen-
dence of metastatic potential .
In addition, the presence ofthis transplantedmammarytumoralso reversibly affectsRATAJCZAK ET AL.
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the periodicity of cell types found in vaginal smears of mice. The more precise na-
ture of the substance or substances that these tumor cells produce, or cause other
cells to produce, whichlengthens the mouse'sestrous cycle, remainsmysterious. The
identification of such asubstance couldopen the door to the discoveryof anew class
of tumor markers for certain endocrine-dependent breast cancers. The isolation,
purification, identification, and production of a"natural" substance that modulates
estrous cycling, if novel, also has potential implications for fertility control.
The differences in lengths of estral periods defined by L alone or C alone found
in this study conflict somewhat with the findings of Voss (22) in which quantities
of L and C were regularly expressed opposite to each other in magnitude. In the
present study, peak quantities of these cell types were not perfectly out of phase,
butoverlapped considerably. This difference may be explained by the differingmetho-
dologies and by the use of different strains of mice.
TestingforHormoneReceptors.
￿
Useful tests upon tumor tissue that predict the ulti-
mate clinical outcome of human breast cancer include tumor cell estrogen and
progesterone receptor concentration determinations (23). A complex, incompletely
understood, yet important relationship between mammary adenocarcinoma, hor-
mones, and their receptors has been established (24, 25). The predictable high-
amplitude hormonal fluxes occurring during each fertility cycle undoubtedly affect
hormone receptor biology within tumor cells and this raises the practical questions
of when in the fertilitycycle to optimally perform diagnostic or prognostic biopsies,
the results ofwhich are routinely obtained to plan breast cancer therapy. There may
well be a span within the menstrual cycle during which the receptor concentrations
most accurately and reproducibly predict prognosis or likely response to hormonal
manipulation. While 65 % of patients classified as being"receptor-positive" respond
to hormone therapy, more than a thirddo not. Obtainingbiopsies at specific phases
of the fertility cycle might improve the predictive accuracy of this invasive and ex-
pensivetest . A data base correlating hormonereceptor concentration andmenstrual
phase of sampling with frequency of response to hormonal treatment and ultimate
outcome is required to adequately investigate this hypothesis.
Implications of Timing ofBreast Cancer Surgery.
￿
The implications of this interactive
communication between tumorand host biologyareof substantial basic andclinical
interest. If the dynamic neurohumoral milieu associated with the lowest incidence
of metastatic diseasecanbe preciselydefined, ourunderstanding ofsome ofthe fun-
damental processes governingthe spread of cancer will be improved. Pharmacologic
mimicking of the neurohumoral state associated with the greatest likelihood of sur-
gical cure before removal of the primary cancer also becomes a real possibility. At
the very least, this kind of knowledge makes it possible to plan an excisional biopsy
or mastectomy to coincide with the occurrence of the menstrual stage associated
with the optimal state of natural resistance to metastatic spread of breast cancer.
Krzanowski (26) observed a statistically significant cycling in immunity as expressed
by T4/T8 lymphocyte ratios throughout the menstrual cycle in healthy women and
concluded that the state of sex cycle at time of surgery may influence the outcome.
Prelimary results showing that NK activity in the spleens of C3HeB/Fej mice
changes predictably during the estrous cycle also argue for the likely relevance of
the effects of these hormonal cycles upon cellular immunity (27).
If our work is confirmed by simple retrospective and prospective epidemiologic82 ESTROUS ROLE IN SURGICAL CURE OF MOUSE BREAST CANCER
studies in human beings that determine the timing of the woman's last menstrual
period relative to the time of primary resection, careful consideration ofwhen in
the fertility cycle to biopsy or resect the breast cancers of cycling women has the
potential to save many thousands of lives worldwide .
Summary
We have studied the effect of estrous stage, as reflected by vaginal cellularity, at
the time of surgical resection of an estrogen receptor-bearing mammary adenocar-
cinoma upon the metastatic potential of that tumor in the C3HeB/Fej mouse . Pres-
ence of the tumor prolonged the length of the estrous cycle by -25% and removal
ofthe tumor returned the cycle to its usual duration . Neither estrous stage at tumor
implant nor size of tumor at resection (within a small range) had significant inde-
pendent effects upon differences observed in the incidence ofsubsequent pulmonary
metastases. However, estrous stage at time ofsurgical removal ofthe tumor, as reflected
by cell types in vaginal smear, markedly affected whether or not metastases ulti-
mately appeared . Because the estrous cycle in mice, comparable to the human men-
strual cycle, reflects high-amplitude, rhythmic changes in hormone concentrations,
it may be that the hormonal status of a woman at the time of tumor resection is
an important determinant ofwhether or not that breast cancer ultimately metastasizes .
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